Loading
A phase 1/2 trial of Elironrasib, Daraxonrasib, Pembrolizumab in non-small-cell lung cancer and small-cell lung cancer, run by Revolution Medicines, Inc., now recruiting.
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC is a phase 1/2 interventional study registered as NCT06162221 by Revolution Medicines, Inc., with 616 participants planned, started 2024-01-18 and due to reach its primary completion in 2027-06. Interventions recorded: RMC-6291, RMC-6236, Pembrolizumab, Cisplatin, Carboplatin. Conditions listed: Non-Small Cell Lung Cancer, NSCLC, KRAS, NRAS, HRAS-mutated NSCLC, KRAS G12C-mutated Solid Tumors, Lung Cancer, Lung Cancer Stage IV, Advanced Solid Tumor, Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Cisplatin.
Shares Revolution Medicines, Pemetrexed, Cisplatin, Carboplatin.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Elironrasib, Revolution Medicines, Daraxonrasib, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Shares Revolution Medicines, Daraxonrasib, Small-cell lung cancer, Non-small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/